Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02731638 · ClinicalTrials.gov registry record · Phase 3
Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
NCT02731638 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 70 participants.
The verdict
NCT02731638, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
Study Summary
Mycotic Antimicrobial Localized Injection (MALIN) is a randomized, masked, two-arm clinical trial investigating intrastromal voriconazole in the treatment of fungal corneal ulcers. There is currently little evidence to guide the treatment of fungal keratitis beyond topical anti-fungal drops, though intrastromal voriconazole and oral antifungal treatments are used as well. This study will provide evidence to guide the treatment of fungal keratitis in the future. The purpose of this study is to determine differences in microbiological cure for 3-day repeat cultures between different antifungal treatments. For this study, there will be 1:1 randomization to one of these two treatment groups: 1) topical natamycin plus intrastromal voriconazole injection or 2) topical natamycin alone.
Interventions
- DRUG Natamycin
- DRUG Intrastromal voriconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02731638
The ClinicalTrials.gov registry entry for NCT02731638 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Natamycin is the first listed.
NCT02731638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02731638 about?
NCT02731638 is a clinical study titled "Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers". Mycotic Antimicrobial Localized Injection (MALIN) is a randomized, masked, two-arm clinical trial investigating intrastromal voriconazole in the treatment of fungal corneal ulcers. There is currently little evidence to guide the treatment of fungal keratitis beyond topical anti-fungal drops, though ...
What is the current status of trial NCT02731638?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2016-09. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02731638?
The interventions under investigation include: Natamycin (DRUG), Intrastromal voriconazole (DRUG).
Who is sponsoring clinical trial NCT02731638?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.